

Sai-Hong I Ou

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3240308/sai-hong-i-ou-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

234
papers

23,858
citations

66
h-index

153
g-index

263
ext. papers

29,069
ext. citations

6.4
avg, IF

6.73
L-index

#	Paper	IF	Citations
234	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 1693-703	59.2	3577
233	Crizotinib in ROS1-rearranged non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 1963-71	59.2	1267
232	Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017 , 377, 829-838	59.2	1221
231	ROS1 rearrangements define a unique molecular class of lung cancers. <i>Journal of Clinical Oncology</i> , 2012 , 30, 863-70	2.2	1170
230	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. <i>Lancet Oncology, The</i> , 2012 , 13, 1011-9	21.7	983
229	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. <i>Lancet Oncology, The</i> , 2011 , 12, 1004-12	21.7	732
228	Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018 , 8, 822-835	24.4	648
227	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. <i>Lancet Oncology, The</i> , 2015 , 16, 830-8	21.7	551
226	Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. <i>Lancet Oncology, The</i> , 2014 , 15, 1119-28	21.7	523
225	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017 , 7, 400-409	24.4	475
224	Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. <i>Cancer Discovery</i> , 2015 , 5, 850-9	24.4	460
223	Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 234-242	21.7	457
222	Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1881-8	2.2	454
221	Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 661-8	2.2	441
220	The KRAS Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. <i>Cancer Discovery</i> , 2020 , 10, 54-71	24.4	413
219	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 4273-81	12.9	411
218	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. <i>Lancet Oncology, The</i> , 2018 , 19, 1654-1667	21.7	361

217	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 942-6	8.9	354
216	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 539-48	21.7	331
215	Landscape of Acquired Resistance to Osimertinib in -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired Fusion. <i>Cancer Discovery</i> , 2018 , 8, 1529-1539	24.4	205
214	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1403-1410	2.2	198
213	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. <i>Cancer Discovery</i> , 2018 , 8, 1227-1236	24.4	194
212	Precision Targeted Therapy with BLU-667 for -Driven Cancers. <i>Cancer Discovery</i> , 2018 , 8, 836-849	24.4	189
211	Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 620-30	8.9	188
210	Targeting MET in Lung Cancer: Will Expectations Finally Be MET?. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 15-26	8.9	186
209	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. <i>Nature Medicine</i> , 2015 , 21, 1038-47	50.5	177
208	Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1493-502	8.9	177
207	Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. <i>Oncologist</i> , 2012 , 17, 1351-75	5.7	175
206	Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1670-4	8.9	166
205	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 613-638	8.9	164
204	Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1199-1206	2.2	155
203	Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1370-1379	2.2	154
202	Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8001-8001	2.2	150
201	Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 549-53	8.9	141
200	Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1691-1701	21.7	136

199	Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. <i>Nature Medicine</i> , 2020 , 26, 47-51	50.5	134
198	The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 784-91	6.1	130
197	Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. <i>Drug Design, Development and Therapy</i> , 2011 , 5, 471-85	4.4	129
196	Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4079-4085	2.2	124
195	Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 83, 407-21	7	120
194	High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. <i>Lung Cancer</i> , 2016 , 98, 59-61	5.9	113
193	MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. <i>Modern Pathology</i> , 2013 , 26, 1632-41	9.8	101
192	Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1625-30	8.9	100
191	ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 447-56	3.5	99
190	Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 37-43	8.9	99
189	The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1570-3	8.9	95
188	Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 880-6	8.9	95
187	Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. <i>Lung Cancer</i> , 2017 , 108, 228-231	5.9	94
186	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2014 , 15, 1433-41	11.7	92
185	Identification of ROS1 rearrangement in gastric adenocarcinoma. <i>Cancer</i> , 2013 , 119, 1627-35	6.4	92
184	Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 1083-93	8.9	92
183	Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 1083-93	8.9	91
182	Acquired Resistance to KRAS Inhibition in Cancer. <i>New England Journal of Medicine</i> , 2021 , 384, 2382-2393	39.2	91

181	KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101974	14.4	90
180	The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. <i>Lung Cancer</i> , 2017 , 103, 27-37	5.9	89
179	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. <i>Oncologist</i> , 2016 , 21, 762-70	5.7	87
178	Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1181-9	8.9	87
177	Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2693-2701	2.2	87
176	Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 932-942	8.9	85
175	Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8032-8032	2.2	83
174	Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. <i>Cancer</i> , 2014 , 120, 2694-703	6.4	81
173	Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1560-1568	8.9	75
172	Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 137-140	8.9	72
171	Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1821-5	8.9	71
170	Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 108-108	2.2	70
169	Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 2044-6	8.9	69
168	Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1312-1323	8.9	65
167	Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an Gene Fusion. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	64
166	Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. <i>Lung Cancer</i> , 2015 , 89, 357-9	5.9	63
165	Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1030-8	8.9	63
164	Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 216-27	8.9	63

163	HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 446-457	8.9	59
162	I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. <i>Lung Cancer</i> , 2015 , 88, 231-4	5.9	58
161	Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 1202-11	8.9	58
160	Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. <i>Oncologist</i> , 2015 , 20, 499-507	5.7	56
159	Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1552-1560	8.9	55
158	Prognostic significance of the non-size-based AJCC T2 descriptors: visceral pleura invasion, hilar atelectasis, or obstructive pneumonitis in stage IB non-small cell lung cancer is dependent on tumor size. <i>Chest</i> , 2008 , 133, 662-9	5.3	54
157	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <i>Lung Cancer</i> , 2019 , 133, 96-102	5.9	53
156	Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 152-156	8.9	52
155	The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 300-10	8.9	52
154	BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. <i>Cancer Discovery</i> , 2016 , 6, 594-600	24.4	52
153	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. <i>Oncotarget</i> , 2015 , 6, 28211-22	3.3	48
152	Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9062-9062	2.2	48
151	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1794-1806	8.9	47
150	Heart rate decrease during crizotinib treatment and potential correlation to clinical response. <i>Cancer</i> , 2013 , 119, 1969-75	6.4	47
149	Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1185-96	8.9	47
148	Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. <i>EBioMedicine</i> , 2018 , 29, 112-127	8.8	46
147	Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 141-144	8.9	46
146	SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). <i>Journal of Thoracic Oncology</i> , 2015 , 10, 387-91	8.9	45

145	Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?. <i>Lung Cancer</i> , 2017 , 106, 110-114	5.9	43
144	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1530-1538	8.9	43
143	ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. <i>Lung Cancer</i> , 2016 , 91, 70-2	5.9	42
142	Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. <i>Oncologist</i> , 2017 , 22, 255-263	5.7	42
141	Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. <i>European Journal of Cancer</i> , 2019 , 109, 154-161	7.5	42
140	Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9011-9011	7.3	42
139	Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. <i>Oncologist</i> , 2015 , 20, 224-6	5.7	41
138	Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 420-7	8.9	40
137	The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials. <i>Oncologist</i> , 2015 , 20, 307-15	5.7	39
136	Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3011-3011	7.2	39
135	Asymptomatic profound sinus bradycardia (heart rate ≤ 5) in non-small cell lung cancer patients treated with crizotinib. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 2135-7	8.9	38
134	Human papilloma virus in non-small cell lung cancer in never smokers: a systematic review of the literature. <i>Lung Cancer</i> , 2014 , 83, 8-13	5.9	37
133	Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1881-8	8.9	37
132	Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. <i>Cancer</i> , 2013 , 119, 2383-90	6.4	36
131	Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 740-763	8.9	36
130	Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 145-151	8.9	35
129	Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. <i>Future Oncology</i> , 2012 , 8, 451-62	3.6	35
128	Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007). <i>Cancer Medicine</i> , 2016 , 5, 617-22	4.8	35

127	Liquid Biopsy to Identify Actionable Genomic Alterations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 978-997	7.1	35
126	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 258-265	8.9	32
125	EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. <i>Lung Cancer</i> , 2020 , 145, 186-194	5.9	31
124	Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. <i>Oncotarget</i> , 2015 , 6, 24320-32	3.3	31
123	Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling. <i>Lung Cancer</i> , 2015 , 88, 352-4	5.9	30
122	U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 4785-4794	12.9	29
121	Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. <i>Lung Cancer</i> , 2017 , 111, 61-64	5.9	29
120	TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling. <i>Lung Cancer</i> , 2016 , 97, 48-50	5.9	28
119	Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 255-264	8.9	28
118	Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management. <i>Lung Cancer</i> , 2015 , 88, 355-9	5.9	25
117	Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment. <i>Oncologist</i> , 2014 , 19, 1008-10	5.7	25
116	Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, 247-254	4.9	25
115	A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib. <i>Lung Cancer</i> , 2016 , 92, 19-21	5.9	24
114	Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Trends in Cancer</i> , 2019 , 5, 677-692	12.5	24
113	Catalog of 5' Fusion Partners in -positive NSCLC Circa 2020. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100015	1.4	24
112	Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. <i>Investigational New Drugs</i> , 2011 , 29, 352-9	4.3	23
111	An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1484-1496	8.9	22
110	Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing. <i>Clinical Cancer Research</i> , 2016 , 22, 3281-5	12.9	22

109	Small-cell lung cancer in never-smokers: a case series with information on family history of cancer and environmental tobacco smoke. <i>Clinical Lung Cancer</i> , 2012 , 13, 75-9	4.9	22
108	A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS3161-TPS3161	2.2	22
107	The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review. <i>Clinical Lung Cancer</i> , 2015 , 16, 334-339.e1	4.9	21
106	Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. <i>Oncologist</i> , 2015 , 20, 1175-81	5.7	21
105	Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 5641-53	4.4	21
104	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. <i>European Journal of Cancer</i> , 2017 , 82, 27-33	7.5	20
103	Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR- β NTRK1-) Non-Small Cell Lung Cancer Globally?. <i>Frontiers in Oncology</i> , 2014 , 4, 58	5.3	20
102	ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 601-608	8.9	20
101	First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 23	22.4	19
100	CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome. <i>Lung Cancer</i> , 2019 , 130, 201-207	5.9	18
99	Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient. <i>Lung Cancer</i> , 2015 , 87, 207-9	5.9	17
98	Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 151-62	3.5	17
97	Neuregulin 1 Fusion-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1354-1359	8.9	16
96	Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1611-1623	8.9	16
95	Crizotinib in Patients With MET-Amplified NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1017-1029	8.9	15
94	Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation. <i>Lung Cancer</i> , 2016 , 96, 15-8	5.9	15
93	Differential response to a combination of full-dose osimertinib and crizotinib in a patient with -mutant non-small cell lung cancer and emergent amplification. <i>Lung Cancer: Targets and Therapy</i> , 2019 , 10, 21-26	2.9	14
92	Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, e124-e127	8.9	14

91	Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy. <i>JAMA Oncology</i> , 2016 , 2, 272-4	13.4	14
90	Rare subtypes of adenocarcinoma of the lung. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1535-42	3.5	14
89	Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS. <i>Chinese Clinical Oncology</i> , 2015 , 4, 20	2.3	14
88	Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. <i>British Journal of Cancer</i> , 2018 , 118, 38-42	8.7	14
87	Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification. <i>Discovery Medicine</i> , 2013 , 15, 333-41	2.5	14
86	First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors (KRYSTAL-1).. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102752	2.2	14
85	Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib. <i>Lung Cancer</i> , 2017 , 110, 32-34	5.9	13
84	ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 966-8	35.1	13
83	Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+ NSCLC: Updated Post NMPA-approval Results from the APOLLO Registrational Trial. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	13
82	MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval. <i>Translational Lung Cancer Research</i> , 2015 , 4, 820-4	4.4	13
81	Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway. <i>Discovery Medicine</i> , 2013 , 16, 7-14	2.5	13
80	Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient. <i>Lung Cancer</i> , 2018 , 123, 83-86	5.9	12
79	MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S438-S439	8.9	11
78	A user's guide to lorlatinib. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 151, 102969	7	11
77	Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, LBA9008-LBA9008	2.3	11
76	A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2513-2513	2.2	11
75	Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9032-9032	2.2	11
74	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in Fusion-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 2899-2909	12.9	11

73	A comparison study of clinicopathologic characteristics of Southern California Asian American Non-small Cell Lung Cancer (NSCLC) patients by smoking status. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 158-68	8.9	10
72	A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8019-8019	2.2	10
71	Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3003-3003	2.2	10
70	Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion. <i>Clinical Lung Cancer</i> , 2017 , 18, e219-e222	4.9	9
69	-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature. <i>Lung Cancer: Targets and Therapy</i> , 2017 , 8, 241-247	2.9	9
68	Crizotinib Inhibits Hyperpolarization-activated Cyclic Nucleotide-Gated Channel 4 Activity. <i>Cardio-Oncology</i> , 2017 , 3,	2.8	9
67	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2020 , 139, 22-27	5.9	9
66	Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 259-268	8.9	9
65	Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. <i>Lung Cancer</i> , 2021 , 158, 126-136	5.9	9
64	Clinicopathologic Features and Response to Therapy of Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2791-2802	2.2	9
63	Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry. <i>Clinical Lung Cancer</i> , 2017 , 18, 535-542	4.9	8
62	MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S378	8.9	8
61	Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 893, 179-187	3.6	8
60	Chemotherapy is beneficial for elderly patients with advanced non-small-cell lung cancer: analysis of patients aged 70-74, 75-79, and 80 or older in Japan. <i>Clinical Lung Cancer</i> , 2012 , 13, 442-7	4.9	8
59	Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2021 , 157, 147-155	5.9	8
58	The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. <i>Oncologist</i> , 2020 , 25, e39-e47	5.7	8
57	in Lung Cancers: Analysis of Patient Cases Reveals Recurrent Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	8
56	Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. <i>Oncologist</i> , 2018 , 23, 776-781	5.7	7

55	Catalog of 5' fusion partners in NSCLC Circa 2020. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100037	1.4	7
54	MA08.01 A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S384-S385	8.9	6
53	Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, LBA9008-LBA9008	2.2	6
52	Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9019-9019	2.2	6
51	How to select the best upfront therapy for metastatic disease? Focus on -rearranged non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2020 , 9, 2521-2534	4.4	6
50	KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. <i>Cancer Treatment Reviews</i> , 2021 , 101, 102309	14.4	6
49	Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Non-Small-Cell Lung Cancer: Histologic Analysis. <i>Clinical Lung Cancer</i> , 2019 , 20, e77-e80	4.9	6
48	Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers. <i>Oncologist</i> , 2017 , 22, 152-157	5.7	5
47	OA08.06 Brigatinib Activity in Patients with ALK+ NSCLC and Intracranial CNS Metastases in Two Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S273-S274	8.9	5
46	Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol. <i>The Cochrane Library</i> , 2018 ,	5.2	5
45	A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, -Rearranged NSCLC. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100045	1.4	5
44	Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase ()-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies. <i>Lung Cancer: Targets and Therapy</i> , 2019 , 10, 125-130	2.9	5
43	Efficacy of Taletrectinib (AB-106/DS-6051b) in NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100108	1.4	5
42	Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations. <i>Molecular Oncology</i> , 2020 , 14, 1731-1739	7.9	4
41	Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in -Rearranged NSCLC: A Report of Two Cases. <i>Lung Cancer: Targets and Therapy</i> , 2020 , 11, 13-18	2.9	4
40	Republished: lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?. <i>Postgraduate Medical Journal</i> , 2014 , 90, 228-35	2	4
39	Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/T790M/G796S) in cis.. <i>Lung Cancer</i> , 2022 , 164, 52-55	5.9	4
38	SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7083-7083	2.2	4

37	Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. <i>Lung Cancer</i> , 2021 , 162, 154-161	5.9	4
36	ALTA-2: Phase III study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. <i>Future Oncology</i> , 2021 , 17, 1709-1719	3.6	4
35	Dramatic response to alectinib in a lung cancer patient with a novel fusion and an acquired ALK T1151K mutation. <i>Lung Cancer: Targets and Therapy</i> , 2018 , 9, 111-116	2.9	4
34	Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib. <i>Journal of Thoracic Oncology</i> , 2021 , 16, e51-e54	8.9	4
33	Patient-reported outcomes in a phase II, North American study of alectinib in patients with -positive, crizotinib-resistant, non-small cell lung cancer. <i>ESMO Open</i> , 2018 , 3, e000364	6	3
32	Dramatic Response to Lorlatinib in a Patient With -Positive Lung Adenocarcinoma With Acquired F2004V Mutation. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	3
31	Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4032-4032	2.2	3
30	Characterization of 1,233 NSCLCs with non-del19/L858R EGFR mutations (EGFRm) using comprehensive genomic profiling (CGP).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9040-9040	2.2	3
29	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic -Rearranged Lung Cancers. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100187	1.4	3
28	A Novel Sequentially Evolved Variant 3 G1202R/S1206Y Double Mutation In Confers Resistance to Lorlatinib: A Brief Report and Literature Review. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100116	1.4	3
27	Identification of Novel fusions and Fusions in NSCLC Plus Additional Novel Fusions in Other Solid Tumors by Whole Transcriptome Sequencing. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100132	1.4	3
26	Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study. <i>BMC Medicine</i> , 2021 , 19, 206	11.4	3
25	A Catalog of 5' Fusion Partners in -Positive NSCLC Circa 2020. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100048	1.4	2
24	Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al. <i>Annals of Oncology</i> , 2014 , 25, 2093	10.3	2
23	Treatment of Advanced Lung Cancer. <i>Clinical Pulmonary Medicine</i> , 2009 , 16, 157-171	0.3	2
22	Continuation of Lorlatinib in ALK-positive NSCLC Beyond Progressive Disease.. <i>Journal of Thoracic Oncology</i> , 2022 ,	8.9	2
21	Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning. <i>Translational Lung Cancer Research</i> , 2015 , 4, 649-52	4.4	2
20	Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an Tyrosine Kinase Inhibitor.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-13	3.6	2

19	Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?. <i>Translational Oncology</i> , 2021 , 14, 1011-1019	4.9	2
18	The effect of tumor size on non-size-based descriptors in staging of stage I non-small cell lung cancer. <i>Chest</i> , 2009 , 135, 1695-1696	5.3	1
17	Survival prognostication in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 785-6	8.9	1
16	Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIA/IIIB non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2006 , 8, 122-9	4.9	1
15	AXL and CDCP1: A roadmap of innate resistance in EGFR mutant NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24003-e24003	2.2	1
14	Testing Patterns and Detection of Exon 20 Insertions in the United States.. <i>JTO Clinical and Research Reports</i> , 2022 , 3, 100285	1.4	0
13	Diverse responses to EGFR-TKIs in patients with concurrent germline and somatic EGFR mutations. <i>Lung Cancer</i> , 2021 , 162, 207-209	5.9	0
12	Missed clinical benefit due to false negatives in testing for EGFR T790M mutations in non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2016 , 9, 131-133	2	0
11	ORIENT-31 as the Sakigake "Charging Samurai" Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the "Meiji Modernization" of Post-3G EGFR TKI Progression?. <i>Lung Cancer: Targets and Therapy</i> , 2022 , 13, 13-21	2.9	0
10	Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements.. <i>Npj Precision Oncology</i> , 2022 , 6, 20	9.8	0
9	Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and pooled analysis of patient outcomes. <i>Current Medical Research and Opinion</i> , 1-34	2.5	0
8	Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR- $\text{N}848\text{K}$ mutation. <i>Lung Cancer</i> , 2018 , 124, 86-89	5.9	
7	To the editor. <i>Journal of Thoracic Oncology</i> , 2014 , 9, e57-e58	8.9	
6	Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Sai-Hong Ignatius Ou and Randall F. Holcombe. <i>Drugs</i> , 2007 , 67, 611-2	12.1	
5	Keeping our fingers crossed on 2(nd) generation EGFR TKIs: is better good enough?. <i>Translational Lung Cancer Research</i> , 2013 , 2, 55-7	4.4	
4	An internet-based survey of factors influencing patients' satisfaction score and factors leading to discontinuation of treatment in lung cancer patients in China.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18871-e18871	2.2	
3	Landscape of kinase rearrangements (kRE) detected in circulating tumor DNA (ctDNA).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12041-12041	2.2	
2	Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy.. <i>Journal of Ophthalmic and Vision Research</i> , 2022 , 17, 130-134 ^{1,2}		

- 1 Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA NSCLC (Except with Alterations?) When Adopting Adjuvant Osimertinib.. *Lung Cancer: Targets and Therapy*, **2022**, 13, 23-31 2.9